Supplementary Table 1 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Adam J. MacNeil,Shun-Chang Jiao,Lori A. McEachern,Yong Jun Yang,Amanda Dennis,Haiming Yu,Zhaolin Xu,Jean S. Marshall,Tong-Jun Lin

DOI: https://doi.org/10.1158/0008-5472.22399527

2023-01-01

Abstract:XLSX file - 27K, Supplementary Table S1. Clinical grading and tumour marker profile information.

What problem does this paper attempt to address?

Supplementary Table 2 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Adam J. MacNeil,Shun-Chang Jiao,Lori A. McEachern,Yong Jun Yang,Amanda Dennis,Haiming Yu,Zhaolin Xu,Jean S. Marshall,Tong-Jun Lin

DOI: https://doi.org/10.1158/0008-5472.22399524

2023-01-01

Abstract:XLSX file - 176K, Supplementary Table S2. Gene expression profile for MKK3dn and MKK3ca cells (vs. WT / MDA-MB-468) using the human breast cancer array (Qiagen, PAHS-131A ), summary of n = 3 experiments.
Supplementary Methods from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Adam J. MacNeil,Shun-Chang Jiao,Lori A. McEachern,Yong Jun Yang,Amanda Dennis,Haiming Yu,Zhaolin Xu,Jean S. Marshall,Tong-Jun Lin

DOI: https://doi.org/10.1158/0008-5472.22399530

2023-01-01

Abstract:PDF file - 116K
Supplementary Figures 1 - 3 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Adam J. MacNeil,Shun-Chang Jiao,Lori A. McEachern,Yong Jun Yang,Amanda Dennis,Haiming Yu,Zhaolin Xu,Jean S. Marshall,Tong-Jun Lin

DOI: https://doi.org/10.1158/0008-5472.22399533

2023-01-01

Abstract:PDF file - 612K, Supplementary Figure S1. Correlation of genomic loss and mRNA expression in breast cancer patients. Supplementary Figure S2. Generation of stable MDA-MB-468 cell lines expressing MKK3dn or MKK3ca. Supplementary Figure S3. MKK3 signalling inhibits Akt activation in MDA-MB-468 cells.
Supplementary Figure Legend from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Adam J. MacNeil,Shun-Chang Jiao,Lori A. McEachern,Yong Jun Yang,Amanda Dennis,Haiming Yu,Zhaolin Xu,Jean S. Marshall,Tong-Jun Lin

DOI: https://doi.org/10.1158/0008-5472.22399536

2023-01-01

Abstract:PDF file - 86K
MAPK Kinase 3 is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Adam J. MacNeil,Shun-Chang Jiao,Lori A. McEachern,Yong Jun Yang,Amanda Dennis,Haiming Yu,Zhaolin Xu,Jean S. Marshall,Tong-Jun Lin

DOI: https://doi.org/10.1158/0008-5472.can-13-1310

IF: 11.2

2014-01-01

Cancer Research

Abstract:Abstract Cancers are initiated as a result of changes that occur in the genome. Identification of gains and losses in the structure and expression of tumor-suppressor genes and oncogenes lies at the root of the understanding of cancer cell biology. Here, we show that the mitogen–activated protein kinase (MAPK) MKK3 suppresses the growth of breast cancer, in which it varies in copy number. A pervasive loss of MKK3 gene copy number in patients with breast cancer is associated with an impairment of MKK3 expression and protein level in malignant tissues. To assess the functional role of MKK3 in breast cancer, we showed in an animal model that MKK3 activity is required for suppression of tumor growth. Active MKK3 enhanced expression of the cyclin-dependent kinase inhibitors p21Cip1/Waf1 and p27Kip1, leading to increased cell-cycle arrest in G1 phase of the cell cycle. Our results reveal the functional significance of MKK3 as a tumor suppressor and improve understanding of the dynamic role of the MAPK pathway in tumor progression. Cancer Res; 74(1); 162–72. ©2013 AACR.
Supplementary Table 3 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Y. Ann Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481001

2023-01-01

Abstract:Supplemental Table 3: top genes that differentiate each cluster of T/NK cells
Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399130

2023-01-01

Abstract:XLSX file - 39K, Gene copy number and ecpression (by Affymetrix and TaqMan) in cell lines used to screen for hits.
Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399124

2023-01-01

Abstract:XLSX file - 37K, Supplementary materials and methods (cell lines, STR profiles, primers, antibodies, molecular reagents).
Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Junfeng Xia,Peilin Jia,Katherine E. Hutchinson,Kimberly B. Dahlman,Douglas Johnson,Jeffrey Sosman,William Pao,Zhongming Zhao

DOI: https://doi.org/10.1158/1535-7163.22500162

2023-01-01

Abstract:XLSX - 28K, Supplementary Table S14. Mutations in 12 potential cancer genes in pan-negative melanoma samples.
Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399142.v1

2023-01-01

Abstract:XLSX file - 37K, Details of the tumour samples use in the article.
Supplementary Table 6 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399127

2023-01-01

Abstract:XLSX file - 29K, Analysis of expression (cancer versus normal) and association with outcome for PSMB4 and SHMT2.
Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399139

2023-01-01

Abstract:XLSX file - 112K, GISTIC analysis of tumour samples.
Supplementary Table 4 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399133

2023-01-01

Abstract:XLSX file - 65K, Gene Ontology analysis of gene over-expressed and amplified in the tumour samples.
Supplementary Table 4 from ATR Inhibition is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Xinyi Tu,Mohamed M. Kahila,Qin Zhou,Jia Yu,Krishna R. Kalari,Liewei Wang,William S. Harmsen,Jian Yuan,Judy C. Boughey,Matthew P. Goetz,Jann N. Sarkaria,Zhenkun Lou,Robert W. Mutter

DOI: https://doi.org/10.1158/1535-7163.22504606

2023-01-01

Abstract:Supplementary Table 4 demonstrates single nucleotide variants, indels, copy number variants and copy number alterations in MCTNBC4
Supplementary Table 3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389576.v1

2023-01-01

Abstract:XLS file - 40K, Abundance of phospho-peptides corresponding to specific signaling molecules in selective serous carcinoma patients
Supplementary Tables 1-2 from the Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer

Kun Guo,Jiujie Cui,Ming Quan,Dacheng Xie,Zhiliang Jia,Daoyan Wei,Liang Wang,Yong Gao,Qingyong Ma,Keping Xie

DOI: https://doi.org/10.1158/1078-0432.22462089.v1

2023-01-01

Abstract:Supplementary Table S1. Clinicopathologic characteristics of TMA Supplementary Table S2. MSI2 expression in the TMA PDAC specimens and clinicopathologic characteristics of the patients from whom the specimens were obtained
Supplementary Table S6 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461785

2023-01-01

Abstract:Supplementary Table S6. Statistical analysis of the effects of PI3K-AKT-mTOR inhibitors on proliferation of HEK293T cells bearing mTOR mutation.
Supplementary Table 1 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Hong Ren,Zhi-Ping Tan,Xin Zhu,Katherine Crosby,Herbert Haack,Jian-Min Ren,Sean Beausoleil,Albrecht Moritz,Gregory Innocenti,John Rush,Yi Zhang,Xin-Min Zhou,Ting-Lei Gu,Yi-Feng Yang,Michael J. Comb

DOI: https://doi.org/10.1158/0008-5472.22389582.v1

2023-01-01

Abstract:XLS file - 31K, Patient Diagnostic Information
Supplementary Tables S2 from CircMMP2(6,7) Cooperates with Β-Catenin and PRMT5 to Disrupt Bone Homeostasis and Promote Breast Cancer Bone Metastasis

Yingru Xu,Xincheng Li,Shuxia Zhang,Miaoling Tang,Ruyuan Yu,Xinyi Liao,Ziwen Li,Man Li,Suwen Chen,Wanying Qian,Libing Song,Zunfu Ke,Jun Li

DOI: https://doi.org/10.1158/0008-5472.25002286

2024-01-01

Abstract:Univariate and Multivariate Analyses of Various Prognostic Parameters in Breast Cancer Patients by Cox-regression Analysis
Supplementary Table 3 from An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

Mark L. McCleland,Adam S. Adler,Yonglei Shang,Thomas Hunsaker,Tom Truong,David Peterson,Eric Torres,Li Li,Benjamin Haley,Jean-Philippe Stephan,Marcia Belvin,Georgia Hatzivassiliou,Elizabeth M. Blackwood,Laura Corson,Marie Evangelista,Jiping Zha,Ron Firestein

DOI: https://doi.org/10.1158/0008-5472.22394589

2023-01-01

Abstract:XLSX file - 25K, RNAi optimization and screening conditions

Supplementary Table 1 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Supplementary Table 2 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Supplementary Methods from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Supplementary Figures 1 - 3 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Supplementary Figure Legend from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

MAPK Kinase 3 is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Supplementary Table 3 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 6 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 4 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 4 from ATR Inhibition is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Supplementary Table 3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Tables 1-2 from the Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer

Supplementary Table S6 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Table 1 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Tables S2 from CircMMP2(6,7) Cooperates with Β-Catenin and PRMT5 to Disrupt Bone Homeostasis and Promote Breast Cancer Bone Metastasis

Supplementary Table 3 from An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors